Search research articles
Contact Us
Filters
Showing results (41-50 of 148) with videos related to
Page
of 15
Sort By:
Cancer
|
May 5, 2020
Oral arsenic trioxide, all-trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: Long-term results and unique prognostic indicators
Harinder S Gill, Rita Yim, Cyrus R Kumana, et al.
Human Vaccines & Immunotherapeutics
|
July 12, 2016
Pembrolizumab (Keytruda)
Gerry Kwok, Thomas C C Yau, Joanne W Chiu, et al.
The Journal of Biological Chemistry
|
November 10, 2017
The peptidyl-prolyl isomerase PIN1 relieves cyclin-dependent kinase 2 (CDK2) inhibition by the CDK inhibitor p27
Chi-Wai Cheng, Ka-Wai Leong, Yiu-Ming Ng, et al.
Annals of Hematology
|
July 27, 2019
Low-dose nivolumab induced durable complete response in relapsed primary central nervous system diffuse large B cell lymphoma
Thomas S Y Chan, Pek-Lan Khong, Rex Au-Yeung, et al.
Hematology (Amsterdam, Netherlands)
|
June 6, 2022
Clonal heterogeneity of polymorphic B-cell lymphoproliferative disease, EBV-positive, iatrogenic/immune senescence: implications on pathogenesis and treatment
Yu-Yan Hwang, Rex Au-Yeung, Rock Y Y Leung, et al.
Annals of Hematology
|
November 10, 2021
Epstein-Barr virus-positive diffuse large B-cell lymphoma after frontline brentuximab vedotin treatment of classical Hodgkin lymphoma
Eric Tse, Rex Au-Yeung, David Chau, et al.
American Journal of Hematology
|
October 3, 2006
Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab
Winnie W Cheung, Eric Tse, Anskar Y H Leung, et al.
Journal of Molecular Biology
|
March 28, 2002
Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein
Eric Tse, M Natividad Lobato, Alan Forster, et al.
European Journal of Haematology
|
August 20, 2014
LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens
Chor Sang Chim, Joycelyn Sim, Sidney Tam, et al.
Seminars in Hematology
|
February 22, 2023
Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management
Eric Tse, Christopher P Fox, Alexander Glover, et al.
Page
of 15
Search research articles
Search
Showing results (41-50 of 148) with videos related to
Sort By:
Page
of 15
Cancer
|
May 5, 2020
Oral arsenic trioxide, all-trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: Long-term results and unique prognostic indicators
Harinder S Gill, Rita Yim, Cyrus R Kumana, et al.
Human Vaccines & Immunotherapeutics
|
July 12, 2016
Pembrolizumab (Keytruda)
Gerry Kwok, Thomas C C Yau, Joanne W Chiu, et al.
The Journal of Biological Chemistry
|
November 10, 2017
The peptidyl-prolyl isomerase PIN1 relieves cyclin-dependent kinase 2 (CDK2) inhibition by the CDK inhibitor p27
Chi-Wai Cheng, Ka-Wai Leong, Yiu-Ming Ng, et al.
Annals of Hematology
|
July 27, 2019
Low-dose nivolumab induced durable complete response in relapsed primary central nervous system diffuse large B cell lymphoma
Thomas S Y Chan, Pek-Lan Khong, Rex Au-Yeung, et al.
Hematology (Amsterdam, Netherlands)
|
June 6, 2022
Clonal heterogeneity of polymorphic B-cell lymphoproliferative disease, EBV-positive, iatrogenic/immune senescence: implications on pathogenesis and treatment
Yu-Yan Hwang, Rex Au-Yeung, Rock Y Y Leung, et al.
Annals of Hematology
|
November 10, 2021
Epstein-Barr virus-positive diffuse large B-cell lymphoma after frontline brentuximab vedotin treatment of classical Hodgkin lymphoma
Eric Tse, Rex Au-Yeung, David Chau, et al.
American Journal of Hematology
|
October 3, 2006
Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab
Winnie W Cheung, Eric Tse, Anskar Y H Leung, et al.
Journal of Molecular Biology
|
March 28, 2002
Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein
Eric Tse, M Natividad Lobato, Alan Forster, et al.
European Journal of Haematology
|
August 20, 2014
LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens
Chor Sang Chim, Joycelyn Sim, Sidney Tam, et al.
Seminars in Hematology
|
February 22, 2023
Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management
Eric Tse, Christopher P Fox, Alexander Glover, et al.
Page
of 15